Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem versus placebo for acute-on-chronic liver failure in cirrhotic adults
NL-OMON60708Phase 2Completed
- Sponsor
- Cellaïon
- Start
- Jan 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute-on-chronic liver failure (ACLF) and Cirrhosis comparing HepaStem with Placebo (2 arms). Primary endpoint: Overall survival at Day 90. Started Jan 2022; status: completed.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosis
Beyond the preview
Go deeper on NL-OMON60708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60708.